Clinical Hematology International

<Previous Article In Issue
Next Article In Issue>
Volume 1, Issue 2, June 2019, Pages 114 - 119

Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute

Authors
Raja Pramanik1, Harish Kancharla1, Sameer Bakhshi1, Atul Sharma1, Ajay Gogia1, Prabhat Malik1, Ranjit Kumar Sahoo1, Atul Batra1, Sanjay Thulkar2, Lalit Kumar1, *
1Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
2Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India
*Corresponding author. Email: lalitaiims@yahoo.com
Corresponding Author
Lalit Kumar
Received 21 March 2019, Accepted 1 May 2019, Available Online 24 May 2019.
DOI
10.2991/chi.d.190504.001How to use a DOI?
Keywords
Engraftment syndrome; Transplant; Autologous
Abstract

Engraftment syndrome (ES) is a clinical syndrome that occurs in the early neutrophil recovery phase following hematopoietic stem cell transplant (HSCT). Although also described for allogenic HSCT, it is basically diagnosed in the context of autologous HSCT. We retrospectively reviewed 171 consecutive HSCTs performed between January 2013 and January 2015 in our Bone Marrow Transplant (BMT) unit and analyzed all cases of noninfectious fever and strong clinical features suggestive of ES in the peri-engraftment period for up to 7 days. We observed the incidence of ES to be 12.3% (16/130) in the autologous and 4.8% (2/41) in the allogeneic cohort. Among plasma cell disorders, which constitute 50% of our study population, the incidence of ES was 19.7%. Among the ES cases of autologous transplants, 81.2% (13/16) patients satisfied the Maiolino criteria (MC) and 87.5% (14/16) patients the Spitzer diagnostic criteria (SC). A total of 68.7% (11/16) patients satisfied both MC and SC, and two patients (12.5%) did not satisfy either (MC− SC−). There was no significant difference in days of hospitalization and usage of supportive care between ES and non-ES patients, and there was no mortality due to ES. On univariate analysis, female patients (p < 0.013) and those with diagnosis of a plasma cell disorder (p < 0.03) had higher risk of ES. In conclusion, the incidence of ES in our study population is consistent with that of many others, but severity evaluation needs exploration in larger cohorts with pragmatically modified diagnostic criteria.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Clinical Hematology International
Volume-Issue
1 - 2
Pages
114 - 119
Publication Date
2019/05/24
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.190504.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Raja Pramanik
AU  - Harish Kancharla
AU  - Sameer Bakhshi
AU  - Atul Sharma
AU  - Ajay Gogia
AU  - Prabhat Malik
AU  - Ranjit Kumar Sahoo
AU  - Atul Batra
AU  - Sanjay Thulkar
AU  - Lalit Kumar
PY  - 2019
DA  - 2019/05/24
TI  - Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute
JO  - Clinical Hematology International
SP  - 114
EP  - 119
VL  - 1
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190504.001
DO  - 10.2991/chi.d.190504.001
ID  - Pramanik2019
ER  -